N2023

Nyhetsarkiv

• "We don't sell our way of life": Indigenous peyote users and the companies trying to cash in (The Guardian, 19. desember)

• MAPS PBC Announces Submission of New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD (MAPS Public Benefit Corporation, press release, 12. desember)

• Post-psychedelic sleep issues (Estatic Integration, 8. desember)

• State-Regulated Psychedelics on a Collision Course With FDA (JAMA Network, 8. desember)

• The Cognitive Dissonance of Drug Censorship on Social Media (Lucid News, 4. desember)

• How Psychedelic Hype is Hurting More People Than We Realize (The Daily Beast, 28. november)

• Raids on magic mushroom dispensaries are a knee-jerk reaction, but taking a blind-eye approach only allows the market to run wild (The Conversation, 19. november)

• Psychedelics can have enormous benefits, but the risks shouldn't be ignored (Vox, 10. november)

• Effects of psychedelic drugs can last for days or weeks, research finds (NBC News, 1. november)

• Psychedelics for addiction recovery: 5 Questions for physician Peter Grinspoon ( The Microdose, 30. oktober)

• California nearly decriminalizes psychedelics - but governor hits brakes (The Guardian, 8. oktober)

• Psychedelic drug MDMA moves closer to US approval following success in PTSD trial (Nature, 14. september)

• Elon Musk Does It. Sergey Brin Does It. Your Boss Might Do It. Welcome to the Workplace Shroom Boom (Wired, 13. september)

• New Clergy Study Echoes Roland Griffith's Early Research (Lucid News, 13. september)

• These Coloradans sought out psilocybin-assisted therapy before it was legal. Here is why (The Denver Post, 31. august)

• Liability insurance for psychedelics: 5 Questions for insurance expert Leslie Nylund (The Microdose, 28. august)

• Psychedelics are poised to change how we age and die (MAPS Bulletin, 25 august)

• Is the therapeutic potential of hallucinogens risky and overhyped? (The Guardian, 19. august)

• Oregon's first psilocybin client: 5 Questions for retired home builder Jim Carroccio (The Microdose, 31. juli)
• The View from Australia: 5 Questions for Psychedelics researcher Paul Liknaitzky (The Microdose, 24. juli)
• Australian psychiatrists can now prescribe MDMA and psilocybin: who can access them and how do they work? (The Guardian, 30. juni)

• Meet The Psychedelic Boom's First Responders (Wired, 29. juni)

• I can't stop looking for my symptoms': The psychology of persistens visuals ( Ecstatic Integration, 23. juni)

• Scientists Now Know Why Psychedelics Conquer Depression Even Without a High (Singularity Hub, 6. juni)

Forskning

The relationship between the default mode network and theory of mind network as revealed by psychedelics - A meta-analysis (ScienceDirect, September 2023) (mer om default mode network (DMN) her og theory of mind (ToM) her)
Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents (Tandofline, 18. august).
Single-Dose Psilocybin Treatment for Major Depressive Disorder (JAMA, 31. juli) (... a 25-mg dose of psilocybin administered with psychological support was associated with a rapid and sustained antidepressant effect.)
5-MeO-DMT shows safety and “ultra-rapid” antidepressant effects in Treatment-Resistant Depression (OPEN Foundation, 16.juli)
Must Psilocybin Always "Assist Psychotherapy"? (The American Journal of Psychiatry, 12. juli) ("The effects observed thus far in the best controlled studies of psychedelic treatment must be attributed to the drug itself and not to psychotherapy. ")
As psychedelics near approval, there is no consensus on how they work (juli)
Psychedelics reopen the social reward learning critical period (juni)
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB (juni)
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2a receptors (februar)

Viktig informasjon --- Innholdet på disse nettsidene er ment som inspirasjon og kunnskapsdeling – ikke som erstatning for medisinsk rådgivning eller psykisk helsehjelp. Dersom du har spørsmål knyttet til helse, anbefaler vi at du snakker med kvalifisert helsepersonell som kan gi deg støtte og veiledning tilpasset din situasjon.

Psilocybin er i dag klassifisert som et ulovlig narkotisk stoff i Norge. Likevel finnes det mange mennesker som ønsker å utforske stoffet på en trygg og meningsfull måte. Pvit jobber derfor for å fremme en ansvarlig og regulert tilnærming utenfor helsevesenet – der individuelle behov og valg får rom, uten krav om diagnose.

© Prosjekt Pvit 2020 - 2025

Page updated

Google Sites

Report abuse